4 edition of Therapeutic Strategies in Lymphoid Malignancy found in the catalog.
August 15, 2005
by Informa Healthcare
Written in English
|Contributions||P. Hillmen (Editor), T.E. Witzig (Editor)|
|The Physical Object|
|Number of Pages||236|
Part of the Cancer Treatment and Research book series (CTAR, volume ) phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer (10) () Current Therapeutic Strategies and New Treatment Paradigms for Follicular Lymphoma. In: Evens A., Blum K. (eds) Non-Hodgkin Lymphoma. Cancer Treatment and Research, vol In a review of the literature on cardioprotection against the toxic effects of anthracyclines given to children with hematologic malignancies including lymphoma, one report found that children with lymphoblastic lymphoma or NHL experienced a protective effect of coenzyme Q10 on cardiac function during anthracycline therapy (Bryant ).
BACKGROUND. Lymph node metastasis is a poor prognostic factor for biliary tract cancers (BTCs). The optimal management of patients who have BTC with positive regional lymph nodes, including the impact of surgery and adjuvant therapy (AT), is unclear. Cell-based vaccination strategies to induce functional tumor-specific T cells in cancer patients have focused on using autologous dendritic cells. An alternative approach is .
The general recommendations for the counselling on and use of fertility preservation methods are presented first in the following review (Fig. 1), followed by the techniques, a description of their efficacy and risks, and finally a discussion of their use in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours (Tables 1,,2, 2,,3. FL is characterized by a proliferation of neoplastic GC B cells, both centrocytes and centroblasts, with at least a partial follicular pattern. 4 The current grading system for FL evaluates the proportion of centrocytes to centroblasts; cases with more centroblasts behave more aggressively and have a higher likelihood of transformation to diffuse large-cell lymphoma. 5 Grade FL is defined.
The third charge of Whitlocke Bulstrode, Esq; to the Grand-Jury, and other juries of the county of Middlesex, at the general quarter-session of the peace held the fourth day of October, 1722, ...
The Sociolinguistics in deaf communities
Victory over all diseases.
The Living plant cell
Early exhibitions of art in Liverpool
Kaw Valley landscapes
Greeks and their eastern neighbours
Racial and ethnic tensions
Letter to the Christian Examiner, being a supplement to Reflections by a churchman
examination of the problems of teacher training in the Northern Ireland context 1922-1984 with particularreference to the principles of catholic education.
philosophy of Bertrand Russell
law of trusts
About MyAccess. If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to. Get this from a library.
Therapeutic strategies in lymphoid malignancies: an immunotherapeutic approach. [Peter Hillmen; Thomas E Witzig;] -- "This unique book brings together a series of topical discussions of how new immunotherapeutic agents can be used successfully to treat lymphoid malignancies.
The contributors are prestigious. One of these new antibodies, alemtuzumab, is a humanised monoclonal antibody against CD52, a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein that is highly expressed on normal T and B lymphocytes and on a large proportion of malignant lymphoid cells, but.
In this review, we summarize the indispensable role of EZH2 in lymphoid development, the variety of mechanisms of EZH2-related oncogenesis in lymphomas, lymphoid leukemias, and myeloma, how Epstein-Barr virus (EBV) impacts EZH2 signaling as a result of virus-host interplay and effective therapeutic strategies to harness EZH2 in different Cited by: 6.
lymphoid malignancies was devised. The WHO classification takes into account morphologic, clinical, immunologic, and genetic information and attempts to divide non-Hodgkin's lymphomas and other lymphoid malignancies into clinical/pathologic entities that have clinical and therapeutic relevance.
As always, the analysis of the genome is the starting point for understanding lymphoid malignancies, with the full sequencing of coding genomes coupled with extensive gene expression profile analysis opening a new era of functional Therapeutic Strategies in Lymphoid Malignancy book, new diagnostic approaches, and targeted therapeutic developments.
Recent biological insights in PMBCL. Although PMBCL has historically been considered a subtype of DLBCL, the World Health Organization’s classification of hematopoietic and lymphoid tumors recognizes it as a distinct entity based on its clinical and immunophenotypical presentation and a gene expression profile that is markedly different from the germinal center B-cell and activated B-cell.
The prognosis for cervical cancer (CCa) patients with lymph node metastasis (LNM) is dismal. Elucidation of the molecular mechanisms underlying LNM may provide clinical therapeutic strategies.
Innate lymphoid cells (ILC) are part of a heterogeneous family of haematopoietic effector cells which lack re-arranged antigen-specific receptors. They promote host defense and contribute to tissue and metabolic homeostasis, wound healing and immune surveillance.
Their role in human cancer immunity is less defined, and therefore we aimed to identify the frequency and phenotype of distinct ILC.
Insights into how cancer cells regulate ILC function represent an important area of unfulfilled need towards the design of therapeutic strategies. An improved understanding of the biology of ILCs could help in the management of immunotherapy-related side effects arising from treatments, including those stemming from immune checkpoint blockade.
Rituximab has completely revolutionised our therapeutic paradigms for patients with B-cell malignancies. The results of a pivotal trial including patients previously treated with chemotherapy demonstrated a response rate of 48% including 6% complete remissions (CRs) and a median duration of response of about a year .These data led to the approval of rituximab by regulatory agencies such.
Colorectal mucosa associated lymphoid tissue (MALT) lymphoma (CML) is rare and comprises only % of the MALT lymphomas. Its etiology and treatment are not well established. The aim of this systematic literature review is trying to characterize CML and analyzing treatment failure cases treated with various therapeutic strategies.
A major goal of the Branch is to translate fundamental biologic insights into novel treatment of human B and T-cell lymphoid malignancies. The major clinical research emphasis is the development of the most effective therapeutic strategies in molecular subtypes of aggressive B-cell lymphomas.
Get this from a library. Therapeutic strategies in lymphoid malignancies: an immunotherapeutic approach. [Peter Hillmen; Thomas E Witzig;] -- Targeted therapies are the focus of much research in oncology.
Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly. Haematology An experienced panel leads the reader through real-life clinical presentations on how to diagnose and manage a variety of clinical cases seen in haematology practice.
Over 30 common and challenging clinical scenarios create a foundation. The term cutaneous T-cell lymphoma (CTCL), introduced inwas used to describe a spectrum of skin-based malignant tumors of T-cell origin.
Immunological studies identified the complex interaction of cytokines released from infiltrating accessory or malignant cells and how such cytokines aid in the maintenance and proliferation of malignant.
Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Review of Anticancer Therapy: Vol. 19, No. 9, pp. Methods: This chapter will review the different subtypes of breast cancer and how receptor status influences therapeutic strategies.
The evolution of adjuvant cytotoxic chemotherapy will be discussed, including how gene expression profiling can help identify patients with hormone receptor positive breast cancer most likely to benefit from therapy.
Hematologic malignancy is the most common childhood cancer and is the most common cancer of the gastrointestinal tract as well. Small bowel lymphomas and colonic tumors, such as Burkitt’s lymphoma of the ileocecal region, comprise 75% to 80% of intestinal malignancies in children.
MUSSHOFF The group of diseases known as malignant lymphomas are, for a number of reasons, of equal interest to theoretical and clinical medicine. New findings in the fields of virology and immunology could conceivably shed some light on the so far unknown etiology of malignant lymphomas.
Tumors of the hematopoietic and lymphoid tissues (American English) or tumours of the haematopoietic and lymphoid malignancies (British English) are tumors that affect the blood, bone marrow, lymph, and lymphatic system.
Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well.Lymphoid malignancies, mainly including lymphocytic leukemia and lymphoma, are a group of heterogeneous diseases.
Although the clinical outcome of patients has been significantly improved with current immuno-chemotherapy, definitive biomarkers remain to be investigated, particularly those reflecting the malignant behavior of tumor cells and those helpful for developing optimal targeted therapy.
Risk-adapted DA-EPOCH-R therapy is effective in adult Burkitt lymphoma regardless of age or HIV status and was well tolerated. Improved therapeutic strategies for adults with CSF involvement are needed (funded by the National Cancer .